Abstract: According to aspects of embodiments described herein, an optical computing device (100) comprises a plurality of input waveguides (101), a photonic meta-surface (103) in contact with the plurality of input waveguides, and a plurality of output waveguides (105) in contact with the transformational meta-surface. The optical computing device may be configured to perform a mathematical operation may be a matrix multiplication. A computer-implemented method (300) of designing an optical computing device includes a plurality of input waveguides, a photonic meta-surface, and a plurality of output waveguides, the method includes exciting each input waveguide one-by-one (303) and measuring the energy at the input region and the output region (305) to determine a contribution of the current input waveguide. The sum of contributions (307) of all input waveguides are compared to a target transformation (315) to determine a loss value used to update a set of design parameters (317).

Abstract: The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.

Abstract: Both single phase lead-free cubic pyrochlore bismuth zinc niobate (BZN)-based dielectric materials with a chemical composition of Bi1.5Zn(0.5+y)Nb(1.5?x)Ta(x)O(6.5+y), with 0?x<0.23 and 0?y<0.9 and films with these average compositions with Bi2O3 particles in an amorphous matrix and a process of manufacture thereof. The crystalline BZNT-based dielectric material has a relative permittivity of at least 120, a maximum applied electric field of at least 4.0 MV/cm at 10 kHz, a maximum energy storage at 25° C. and 10 kHz of at least 50 J/cm3 and a maximum energy storage at 200° C. and 10 kHz of at least 22 J/cm3. The process is a wet chemical process that produces thin films of Bi1.5Zn(0.5+y)Nb(1.5?x)Ta(x)O(6.5+y) without the use of 2-methoxyethanol and pyridine.

Abstract: An electronic circuit to increase voltages from one or more energy sources. The electronic circuit can include a first set of capacitors and a second set of capacitors, and a first set of switches associated with the first set of capacitors and a second set of switches associated with the second set of capacitors. Also included is at least one energy source and an external load. The first and second set of capacitors, first and second set of switches, the at least one energy source, and the external load are arranged and connected such that the first set of capacitors is connected to the at least one energy source in parallel while the second set of capacitors is connected to the external load in series, and vice versa.

Abstract: A gated microelectronic device is provided that has a source with a source ohmic contact with the source characterized by a source dopant type and concentration. A drain with a drain ohmic contact with the drain characterized by a drain dopant type and concentration. An intermediate channel portion characterized by a channel portion dopant type and concentration. An insulative dielectric is in contact with the channel portion and overlaid in turn by a gate. A gate contact applies a gate voltage bias to control charge carrier accumulation and depletion in the underlying channel portion. This channel portion has a dimension normal to the gate which is fully depleted in the off-state. The dopant type is the same across the source, drain and the channel portion of the device. The device on-state current is determined by the doping and, unlike a MOSFET, is not directly proportional to device capacitance.

Abstract: Systems and methods for microbial processes of generating products such as electrical power, hydrogen gas and methane, are provided according to aspects of the present invention which include a reaction chamber having a wall defining an interior of the reaction chamber and an exterior of the reaction chamber; an anode at least partially contained within an anode compartment of the reaction chamber; a plurality of exoelectrogenic microorganisms disposed in the anode compartment; a cathode at least partially contained within a cathode compartment of the reaction chamber; a conductive conduit for electrons in electrical communication with the anode and the cathode; and a reverse electrodialysis stack comprising a plurality of plurality of alternating anion selective barriers and cation selective barriers disposed between the anode and the cathode defining one or more saline material compartments and one or more lower-saline material compartments.

Abstract: This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions.

Abstract: This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions.